QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.108.024612v1 37/2/359    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shukla, S. Articles by Ambudkar, S. V. Search for Related Content PubMed PubMed Citation Articles by Shukla, S. Articles by Ambudkar, S. V.

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

Laboratory of Cell Biology (S.S., S.V.A.) and Medical Oncology Branch (R.W.R., S.E.B.), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Sunitinib malate (Sutent, SU11248) is a small-molecule receptor tyrosine kinase inhibitor that inhibits cellular signaling of multiple targets such as the platelet-derived growth factor receptors and the vascular endothelial growth factor receptors and is used in the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors. Because tyrosine kinase inhibitors are known to increase the p.o. bioavailability and brain penetration of chemotherapy drugs in animal models, we sought to examine the effect of sunitinib on the ATP-binding cassette (ABC) drug transporters P-glycoprotein (P-gp, ABCB1), the multidrug resistance-associated protein 1 (ABCC1), and ABCG2, which are known to transport a wide variety of anticancer drugs. In this study, we show that sunitinib inhibits P-gp- and ABCG2-mediated efflux of fluorescent substrates in cells overexpressing these transporters. In 4-day cytotoxicity assays, at a nontoxic concentration (2 µM) sunitinib was able to partially reverse drug resistance mediated by P-gp and completely reverse resistance mediated by ABCG2. We further show a direct interaction of sunitinib with the substrate binding pocket of these transporters as it inhibited binding of the photoaffinity substrate [¹²⁵I]iodoarylazidoprazosin to P-gp (IC₅₀ = 14.2 µM) and ABCG2 (IC₅₀ = 1.33 µM). Sunitinib stimulated the ATP hydrolysis by both transporters in a concentration-dependent manner. Conformation-sensitive antibody binding assays with the P-gp- and ABCG2-specific antibodies, UIC2 and 5D3, respectively, also confirmed the interaction of sunitinib with these transporters. Taken together, this is the first report showing that sunitinib inhibits transport mediated by ABC drug transporters, which may affect the bioavailability of drugs coadministered with sunitinib.

This article has been cited by other articles:

				S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M. A. Rudek, A. Sparreboom, and S. D. Baker Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters Clin. Cancer Res., October 1, 2009; 15(19): 6062 - 6069. [Abstract] [Full Text] [PDF]

				N. P. van Erp, K. Eechoute, A. A. van der Veldt, J. B. Haanen, A. K.L. Reyners, R. H.J. Mathijssen, E. Boven, T. van der Straaten, R. F. Baak-Pablo, J. A.M. Wessels, et al. Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity J. Clin. Oncol., September 10, 2009; 27(26): 4406 - 4412. [Abstract] [Full Text] [PDF]